

## Management changes resulting from sale of DIAsource

1 September 2017

Anteo Diagnostics Limited (ASX: ADO) (**Anteo** or **Company**) advises that, due to the sale of DIAsource ImmunoAssays SA (**DIAsource**) as announced today, Dr Jef Vangenechten, Group Chief Executive Officer, has resigned from his position with Anteo effective immediately.

Dr John Hurrell the Company's current Non-Executive Chairman will be appointed as Interim Executive Chairman of the Company for an initial period of 3 months and domiciled in Australia while the Board searches for an appropriate Chief Executive Officer ("**CEO**") and evaluates the Company's strategy.

Dr Hurrell will commence his duties immediately and will be paid AUD \$20,000 per month in addition to his existing Non-Executive Chairman's fees of AUD \$6,666.67 per month (AUD \$80,000 per annum). The Company has the right to terminate his appointment as Interim Executive Chairman with one month's notice at which point Dr Hurrell will resume his Non-Executive Chairman's role and non-executive remuneration at the end of that period.

Commenting on the management changes Mr Alan Studley, independent director, stated:

"We thank Jef for his leadership of the Company while DIAsource was part of the group and wish him all the best in his continued role with DIAsource and his future endeavours.

"Dr Hurrell brings over 30 years experience in the global biotechnology and life science industries and is well placed to assist the company with evaluating its strategy going forward and will provide Anteo with valuable leadership while the Company undertakes the search for a suitable CEO."

---

### ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

For more information, please visit [www.anteodx.com](http://www.anteodx.com)